- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07726953
Full-Course ECMO Strategy for Moderate-to-Severe ARDS
Establishment and Evaluation of a Full-Course ECMO Management Strategy for Patients With Moderate-to-Severe ARDS
China faces major challenges in the ECMO management of patients with moderate-to-severe ARDS, including substantial heterogeneity in clinical practice, low weaning success rates, and high complication rates. A key underlying reason is the lack of a standardized full-course management pathway that is applicable to real-world clinical practice in China. This study focuses on the construction and evidence-based evaluation of a precision full-course ECMO management pathway for patients with moderate-to-severe ARDS, aiming to address fragmented care processes and delayed quality improvement.
The study includes three main components. First, multidisciplinary consensus and evidence-based findings will be integrated to develop a standardized management pathway covering the full chain of assessment, initiation, maintenance, weaning, and rehabilitation. Second, a nationwide multicenter real-world study with a before-and-after design will be conducted to systematically evaluate the clinical effectiveness of this pathway in reducing mortality and complications and improving patient outcomes. Third, a closed-loop dynamic optimization system based on "pathway-data-feedback-improvement" will be established. With the support of an intelligent data platform and multidisciplinary review mechanisms, the pathway will be continuously updated and refined.
Through this study, a reproducible, traceable, and evaluable full-course ECMO management strategy is expected to be established. The study will also build a national collaborative research network and support the development of living clinical guidance, promoting the transition of ECMO care in China from experience-based practice toward standardized, homogeneous, and intelligent management, and providing a key technical framework and practical model for improving critical care.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
This study focuses on the establishment, clinical evaluation, and dynamic optimization of a full-course ECMO management pathway for patients with moderate-to-severe ARDS.
First, a standardized full-course ECMO management pathway will be developed based on evidence-based medicine and multidisciplinary collaboration. The pathway will cover the entire clinical process, including assessment of ECMO indications, ECMO initiation, maintenance management, complication prevention and management, ECMO weaning, rehabilitation, and follow-up. The aim is to standardize key clinical decision points and improve the homogeneity of ECMO care across participating centers.
Second, the clinical effectiveness of the full-course ECMO management pathway will be evaluated through a multicenter, real-world, before-and-after clinical study. Patients treated before implementation of the pathway will serve as the control group, while patients treated after implementation will receive care according to the standardized pathway. The study will systematically assess whether implementation of the pathway improves clinical outcomes in patients with moderate-to-severe ARDS receiving ECMO.
Third, a closed-loop system for pathway implementation and dynamic optimization will be established. This system will follow a "pathway-data-feedback-improvement" model. Based on updated guidelines and evidence generated from this study, key intervention points, process key performance indicators, and quality indicators will be defined. A unified electronic pathway and data dictionary will be used across participating centers. Physicians, respiratory therapists, and nurses will record key parameters and reasons for pathway deviations through an intelligent data platform.
Regular multidisciplinary reviews will be conducted monthly or quarterly to evaluate pathway implementation, identify process barriers, analyze center-level variation, and review the root causes of adverse events. Statistical process control, cumulative sum analysis, and risk-adjusted benchmarking may be used to support quality monitoring and continuous improvement. Based on the accumulated clinical data and evidence, living clinical guidance or practice recommendations will be updated iteratively.
The final goal of this study is to establish a reproducible, traceable, and evaluable full-course ECMO management pathway for patients with moderate-to-severe ARDS, thereby supporting standardized and homogeneous ECMO care across multiple centers.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: yingzi Huang, M.D.
- Номер телефона: 18271428804
- Электронная почта: yz_huang@126.com
Места учебы
-
-
-
Beijing, Китай
- Рекрутинг
- Beijing AnZhen Hospital, Capital Medical University
-
Контакт:
- Zhongtao Du
-
Changchun, Китай
- Еще не набирают
- The Second Hospital of Jilin University
-
Chengdu, Китай
- Еще не набирают
- West China Tianfu Hospital, Sichuan University
-
Chenzhou, Китай
- Еще не набирают
- The First People's Hospital of Chenzhou
-
Dalian, Китай
- Рекрутинг
- The Second Affiliated Hospital of Dalian Medical University
-
Fuzhou, Китай
- Рекрутинг
- Fuzhou University Affiliated Provincial Hospital
-
Контакт:
- Shang
-
Guangzhou, Китай
- Рекрутинг
- The First Affiliated Hospital of Guangzhou Medical University
-
Контакт:
- Yan Wang
-
Hangzhou, Китай
- Рекрутинг
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Контакт:
- Xie
-
Hangzhou, Китай
- Еще не набирают
- Affiliated Hangzhou First People's Hospital of Westlake University School of Medicine
-
Ha’erbin, Китай
- Еще не набирают
- The First Affiliated Hospital of Harbin Medical University
-
Ha’erbin, Китай
- Рекрутинг
- The Second Affiliated Hospital of Harbin Medical University
-
Контакт:
- Hongliang Wang
-
Huai'an, Китай
- Еще не набирают
- Huai'an first people's hospital
-
Jinan, Китай
- Рекрутинг
- Qilu Hospital of Shandong University
-
Контакт:
- Hao Wang
-
Kunshan, Китай
- Еще не набирают
- The First People's Hospital of Kunshan
-
Lanzhou, Китай
- Еще не набирают
- The First Hospital of Lanzhou University
-
Lianyungang, Китай
- Еще не набирают
- The first people's hospital of Lianyungang
-
Liuzhou, Китай
- Рекрутинг
- Liuzhou People's Hospital
-
Контакт:
- Wenfang Jiang
-
Nanjing, Китай
- Еще не набирают
- Jiangsu Province Hospital
-
Nanjing, Китай
- Рекрутинг
- Zhongda Hospital Southeast University
-
Контакт:
- Xiaojing Wu
- Номер телефона: 13951876234
- Электронная почта: 36410257@qq.com
-
Nanjing, Китай
- Рекрутинг
- Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School)
-
Контакт:
- Danjiang Dong
-
Nanning, Китай
- Еще не набирают
- The People's Hospital of Guangxi Zhuang Autonomous Region
-
Nanning, Китай
- Еще не набирают
- The First Affiliated Hospital of Guangxi Medical University
-
Nanning, Китай
- Еще не набирают
- The Second Affiliated Hospital of Guangxi Medical University
-
Nantong, Китай
- Еще не набирают
- Affiliated Hospital of Nantong University
-
Ningxiang, Китай
- Еще не набирают
- General Hospital of Ningxia Medical University
-
Qinghai, Китай
- Еще не набирают
- The Affiliated Hospital of Qinghai University
-
Quzhou, Китай
- Рекрутинг
- Quzhou people's Hospital
-
Sichuan, Китай
- Рекрутинг
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (SAMS&SPPH, Affiliated Hospital of UESTC)
-
Контакт:
- Hongli He
-
Suining, Китай
- Еще не набирают
- Suining Central Hospital
-
Suzhou, Китай
- Еще не набирают
- The First Affiliated Hospital of Soochow University
-
Wuxi, Китай
- Рекрутинг
- Wuxi People's Hospital
-
Контакт:
- Hongyang Xu
-
Xi'an, Китай
- Рекрутинг
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Контакт:
- jing Geng
-
Xiamen, Китай
- Еще не набирают
- The First Affiliated Hospital of Xiamen University
-
Xinyang, Китай
- Еще не набирают
- Xinyang Central Hospital
-
Xuzhou, Китай
- Еще не набирают
- The Affiliated Hospital of Xuzhou Medical Universit
-
Yangzhou, Китай
- Еще не набирают
- Northern Jiangsu People's Hospital
-
Zhengzhou, Китай
- Рекрутинг
- Henan Provincial People's Hospital
-
Контакт:
- Huanzhang Shao
-
Zhengzhou, Китай
- Еще не набирают
- The First Affiliated Hospital of Zhengzhou University
-
Zhongshan, Китай
- Еще не набирают
- Zhongshan Hospital of Traditional Chinese Medicine
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Описание
Inclusion Criteria:
- 1. Age 18 years or older. 2. Diagnosed with moderate-to-severe acute respiratory distress syndrome according to the global definition of ARDS.
Exclusion Criteria:
- 1. Patients with tracheostomy before screening. 2. Patients who have received lung transplantation or are receiving venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation.
3. Patients with cardiogenic shock requiring venoarterial ECMO or venoarterial-venous ECMO support.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Другой: Pre-Implementation Usual Care
Participants in this arm are patients with moderate-to-severe ARDS who received ECMO before implementation of the standardized full-course ECMO management pathway.
Clinical care will be provided according to usual practice at each participating center, including ECMO initiation, maintenance, complication management, weaning, and rehabilitation based on local protocols and clinician judgment.
|
Usual care refers to ECMO management provided before implementation of the standardized full-course ECMO management pathway.
Clinical decisions are made according to local practice and clinician judgment at each participating center.
|
|
Экспериментальный: Post-Implementation ECMO Management Pathway
Participants in this arm are patients with moderate-to-severe ARDS who receive ECMO after implementation of the standardized full-course ECMO management pathway.
Clinical care will follow the pathway covering assessment of ECMO indications, ECMO initiation, maintenance management, complication prevention and management, weaning assessment, rehabilitation, and follow-up.
Individualized adjustments are allowed according to patient condition, and pathway deviations will be recorded.
|
The intervention is a standardized full-course ECMO management pathway for patients with moderate-to-severe ARDS.
The pathway covers assessment of ECMO indications, ECMO initiation, cannulation and anticoagulation strategies, mechanical ventilation management, hemodynamic and fluid management, infection prevention, analgesia and sedation, nutrition and rehabilitation, complication prevention and management, weaning assessment, discharge, and follow-up.
Individualized adjustments are allowed according to patient condition, and pathway deviations will be recorded for quality improvement and subsequent analysis.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
90-Day All-Cause Mortality
Временное ограничение: From ECMO initiation to 90 days after ECMO initiation
|
From ECMO initiation to 90 days after ECMO initiation
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
28-Day All-Cause Mortality
Временное ограничение: 28 days after ECMO initiation
|
The proportion of participants who die from any cause within 28 days after ECMO initiation will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
28 days after ECMO initiation
|
|
Successful Liberation From Mechanical Ventilation
Временное ограничение: From initiation of invasive mechanical ventilation to 7 days after liberation from mechanical ventilation, assessed up to hospital discharge
|
Successful liberation from mechanical ventilation is defined as survival without reintubation or death within 7 days after extubation in patients without tracheostomy, or survival without reconnection to mechanical ventilation or death within 7 days afte
|
From initiation of invasive mechanical ventilation to 7 days after liberation from mechanical ventilation, assessed up to hospital discharge
|
|
ICU Mortality
Временное ограничение: From ICU admission to ICU discharge or death, assessed up to 90 days after ECMO initiation
|
The proportion of participants who die during the ICU stay will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
From ICU admission to ICU discharge or death, assessed up to 90 days after ECMO initiation
|
|
ICU Length of Stay
Временное ограничение: From ICU admission to ICU discharge, assessed up to 90 days after ECMO initiation
|
ICU length of stay is defined as the number of days from ICU admission to ICU discharge or death.
|
From ICU admission to ICU discharge, assessed up to 90 days after ECMO initiation
|
|
Respiratory Support at ICU Discharge
Временное ограничение: At ICU discharge, assessed up to 90 days after ECMO initiation
|
Respiratory support status at ICU discharge will be recorded, including tracheostomy, invasive mechanical ventilation, noninvasive ventilation or high-flow nasal cannula, conventional oxygen therapy, or no oxygen therapy.
|
At ICU discharge, assessed up to 90 days after ECMO initiation
|
|
Hospital Mortality
Временное ограничение: From hospital admission to hospital discharge or death, assessed up to 90 days after ECMO initiation
|
The proportion of participants who die during hospitalization will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
From hospital admission to hospital discharge or death, assessed up to 90 days after ECMO initiation
|
|
Hospital Length of Stay
Временное ограничение: From hospital admission to hospital discharge, assessed up to 90 days after ECMO initiation
|
Hospital length of stay is defined as the number of days from hospital admission to hospital discharge or death.
|
From hospital admission to hospital discharge, assessed up to 90 days after ECMO initiation
|
|
Respiratory Support at Hospital Discharge
Временное ограничение: At hospital discharge, assessed up to 90 days after ECMO initiation
|
Respiratory support status at hospital discharge will be recorded, including tracheostomy, invasive mechanical ventilation, noninvasive ventilation or high-flow nasal cannula, conventional oxygen therapy, or no oxygen therapy.
|
At hospital discharge, assessed up to 90 days after ECMO initiation
|
|
Incidence of ECMO-Related Complications
Временное ограничение: From ECMO initiation to 48 hours after ECMO decannulation
|
The incidence of ECMO-related complications will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
ECMO-related complications include major bleeding, minor bleeding, mechanical or circuit thrombosis, patient-related thrombosis, hospital-acquired infection during ECMO, hemolysis, cannulation-related complications, acute kidney injury, and oxygenator replacement.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Major Bleeding Events
Временное ограничение: From ECMO initiation to 48 hours after ECMO decannulation
|
Major bleeding is defined as bleeding that meets at least one of the following criteria: life-threatening bleeding, including intracranial bleeding, retroperitoneal bleeding, cardiac tamponade, or bleeding leading to hemorrhagic shock; bleeding requiring surgical intervention; or transfusion of at least 2 units of red blood cells within 24 hours due to active bleeding.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Minor Bleeding Events
Временное ограничение: From ECMO initiation to ECMO decannulation
|
Mechanical or circuit thrombosis is defined as thrombus formation observed or diagnosed within the extracorporeal circuit during ECMO support, including thrombosis in the ECMO oxygenator, pump head, tubing, connectors, or other circuit components.
|
From ECMO initiation to ECMO decannulation
|
|
Patient-Related Thrombotic Events
Временное ограничение: From ECMO initiation to 48 hours after ECMO decannulation
|
Patient-related thrombotic events are defined as thrombotic or embolic events occurring within the patient's vascular system and confirmed by clinical findings, imaging, or autopsy.
Events include deep vein thrombosis, pulmonary embolism, and ischemic stroke.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Hospital-Acquired Infection During ECMO
Временное ограничение: From 24 hours after ECMO initiation to 48 hours after ECMO decannulation
|
Hospital-acquired infection during ECMO is defined as infection occurring more than 24 hours after ECMO initiation and up to 48 hours after ECMO decannulation.
Infection sites include bloodstream infection, respiratory tract infection or ventilator-associated pneumonia, mediastinitis, cannulation-site or surgical-site infection, urinary tract infection, or other documented infection sites.
|
From 24 hours after ECMO initiation to 48 hours after ECMO decannulation
|
|
Hemolysis During ECMO
Временное ограничение: From ECMO initiation to ECMO decannulation
|
Hemolysis is defined as plasma-free hemoglobin greater than 500 mg/L, equivalent to greater than 50 mg/dL, after ECMO cannulation.
|
From ECMO initiation to ECMO decannulation
|
|
Cannulation-Related Complications
Временное ограничение: From ECMO cannulation to 48 hours after ECMO decannulation
|
Cannulation-related complications include limb ischemia, pseudoaneurysm, arteriovenous fistula, vascular dissection, or other vascular complications related to ECMO cannulation.
Limb ischemia is defined as impaired distal perfusion of the cannulated limb requiring clinical evaluation or intervention.
|
From ECMO cannulation to 48 hours after ECMO decannulation
|
|
Acute Kidney Injury During ECMO
Временное ограничение: From ECMO initiation to ECMO decannulation
|
Acute kidney injury during ECMO will be assessed according to KDIGO criteria and classified as stage 1, stage 2, or stage 3.
The need for continuous renal replacement therapy will also be recorded.
|
From ECMO initiation to ECMO decannulation
|
|
Oxygenator Replacement
Временное ограничение: From ECMO initiation to ECMO decannulation
|
Oxygenator replacement is defined as replacement of the ECMO oxygenator for any reason during ECMO support, including oxygenator thrombosis, gas exchange dysfunction, increased transmembrane pressure, hemolysis, or other clinical indications.
|
From ECMO initiation to ECMO decannulation
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 2026ZDSYLL081-P01
- 2026ZD0555505 (Другой номер гранта/финансирования: National Key R&D Program of China)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .